Identification of high-risk monomorphic post-transplant lymphoproliferative disorder following solid organ transplantation

References

• Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Engl J Med. 2018;378:549–562.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
   PubMed Web of Science ®Google Scholar
• Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306:1891–1901.
   PubMed Web of Science ®Google Scholar
• de Fijter JW. Cancer and mTOR inhibitors in transplant recipients. Transplantation. 2017;101:45–55.
   PubMed Web of Science ®Google Scholar
• Caillard S, Porcher R, Provot F, et al. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a Nationwide French Registry and the Development of a New Prognostic Score. J Clin Oncol. 2013;31:1302–1309.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Cin Oncol. 2012;30:3452–3459.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114:2273–2279.
   PubMed Web of Science ®Google Scholar
• Luskin MR, Heil DS, Tan KS, et al. The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder. Am J Transplant. 2015;15:2665–2673.
   PubMed Web of Science ®Google Scholar
• Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 1991;65:1107–1115.
   PubMed Web of Science ®Google Scholar
• Poirel HA, Bernheim A, Schneider A, et al. Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: correlation with histopathological subcategories and EBV status. Transplantation. 2005;80:176–184.
   PubMed Web of Science ®Google Scholar
• Djokic M, Beau MML, Swinnen LJ, et al. Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities. Genes Chromosomes Cancer. 2006;45:313–318.
   PubMed Web of Science ®Google Scholar
• Morscio J, Dierickx D, Tousseyn T. Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: What do we know so far? Clin Dev Immunol. 2013; 2013:150813–150835.
   Google Scholar
• Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant. 2011;11:336–347.
   PubMed Web of Science ®Google Scholar
• Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for post-transplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71:1076–1088.
   PubMed Web of Science ®Google Scholar
• Trappe RU, Dierickx D, Zimmermann H, et al. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an International, Prospective, Multicenter Phase II Trial. J Clin Oncol. 2017;35:536–543.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Li L, Li Y, Que X, et al. Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: a systematic review and meta-analysis. Sci Rep. 2018;8:6267
   PubMed Web of Science ®Google Scholar
• Mahmoud AZ, George TI, Czuchlewski DR, et al. Scoring of MYC protein expression in diffuse large B-cell lymphomas: concordance rate among hematopathologists. Mod Pathol. 2015;28:545–551.
   PubMed Web of Science ®Google Scholar
• Li S, Seegmiller AC, Lin P, et al. B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas. Mod Pathol. 2015;28:208–217.
   PubMed Web of Science ®Google Scholar
• Landsburg DJ, Falkiewicz MK, Petrich AM, et al. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. Br J Haematol. 2016;175:631–640.
   PubMed Web of Science ®Google Scholar
• Yoon SO, Jeon YK, Paik JH, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008;53:205–217.
   PubMed Web of Science ®Google Scholar
• Beà S, Colomo L, López-Guillermo A, et al. Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas. J Clin Oncol. 2004;22:3498–3506.
   PubMed Web of Science ®Google Scholar
• Pedersen M, Gang AO, Poulsen TS, et al. MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations. Eur J Haematol. 2014;92:42–48.
   PubMed Web of Science ®Google Scholar
• Stasik CJ, Nitta H, Zhang W, et al. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica. 2010;95:597–603.
   PubMed Web of Science ®Google Scholar
• Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Cin Oncol. 2010;28:1038–1046.
   PubMed Web of Science ®Google Scholar
• Michonneau D, Suarez F, Lambert J, et al. Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: a monocentric study over three decades. Nephrol Dial Transplant. 2013;28:471–478.
   PubMed Web of Science ®Google Scholar